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Abstract Genome-wide DNA hypermethylation induced by 
3'-azido-3'-deoxythymidine (AZT) has been suggested to be 
involved in the development of AZT resistance. We used a CD4 
T-lymphoblastoid CEM line and its AZT-resistant MT500 
variant with reduced thymidine kinase activity. Evaluation of 
total DNA methylation, after AZT treatment, failed to show an 
increase in the 5-methylcytosine l vel in both parental and AZT- 
resistant cells. The effect was instead observed at a more specific 
gene level, on the three HpaII sites present in exon 1 of the 
human thymidine kinase gene. These results suggest that AZT 
treatment can induce site-specific hypermethylation, even in the 
absence of a more general DNA hypermethylating effect. 
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der conditions everely affecting cell viability. Moreover, only 
scanty information is available about the methylation status 
of specific sites of the TK gene after exposure to AZT. 
This paper reports data concerning the effects of AZT on 
human CD4 T-lymphoblastoid CEM cell line and on its de- 
rived AZT-resistant cell variant, where a reduced TK activity 
has been previously reported [I0]. In particular, we investi- 
gated the effects of AZT on the total DNA methylation as 
well as on specific methylation sites present in the TK gene. A 
hypermethylating effect was found, in the absence of both 
overall DNA hypermethylation and of any great loss of cell 
viability, at the analyzed TK sites, after AZT treatment of 
CEM cells and of its derived AZT-resistant cell variant. 
This phenomenon, which was more marked in the resistant 
cells, could be the molecular basis for the transcriptional in- 
activation of the TK gene. 
1. Introduction 2. Materials and methods 
The clinical benefits of 3'-azido-3'-deoxythymidine (AZT) 
treatment in A IDS patients are often reduced, especially after 
prolonged therapy, by the appearance of drug resistance [1 3]. 
Mutations in the reverse transcriptase (RT) gene of human 
immunodeficiency virus (HIV-1) [4] and cell-mediated mech- 
anisms [5,6] have both been suggested as possible factors un- 
derlying the development of clinical resistance. Antiviral AZT 
efficacy depends on its initial transformation to AZT mono- 
phosphate (AZT-MP) by cellular thymidine kinase (TK), fol- 
lowed by further phosphorylation steps to AZT diphosphate 
and AZT triphosphate (AZT-TP), catalyzed by thymidylate 
kinase and pyrimidine nucleoside diphosphate kinase, respec- 
tively. The last product inhibits HIV-1 replication by inter- 
rupting the viral DNA chain elongation [7]. Low levels of TK  
activity could therefore induce a decrease in the amount of 
AZT-MP available for AZT-TP synthesis, thus reducing the 
therapeutic efficacy of AZT. 
Enzymatic DNA methylation at CpG dinucleotides i con- 
sidered to be one of the mechanisms involved in the control of 
gene expression in eukaryotic cells [8]. Consequently, a ge- 
nome-wide DNA hypermethylation has been suggested as a 
major mechanism in the development of resistance by inhibi- 
tion of transcription of the TK gene [5,9], although only un- 
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2. I. Cell cultures 
The human CD4 T-lymphoblastoid CEM line was kindly provided 
by Dr. W.T. Beck (Memphis, TN, USA). The AZT-resistant cell line 
variant was obtained by exposure of the parental CEM cells to in- 
creasing concentrations of AZT (Sigma Chemical Co., St. Louis, MO, 
USA). To this purpose, CEM cells were initially propagated in the 
presence of 1 laM AZT. 2-fold increasing concentrations of AZT were 
then added to the culture medium and the cells were allowed to grow 
until they reached a cell density of 10 6 cells/ml. After approx. 2 
months a stable CEM cell variant actively proliferating in the presence 
of 32 laM AZT was isolated. An additional 2 months of drug selection 
produced an AZT cell variant resistant to 2 mM AZT, named MT500. 
The cells were maintained in RPMI-1640 medium supplemented with 
10 mM HEPES, 2X 10 ~ M 2-mercaptoethanol, 2 mM L-glutamine, 
10% fetal calf serum (FCS) and antibiotics. MT500 were routinely 
cultured in the presence of AZT (2 mM). Cell viability was determined 
by MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bro- 
mide, Sigma) assay [10]. 
2.2. Determination of total DNA methylation 
Cells were exposed to various AZT concentrations for 48 h in the 
presence of 2 laCi/ml [6-:~H]uridine (Du Pont-New England Nuclear, 
Bad Homburg, Germany, 24 Ci/mmol). 5-Methylcytosine content was 
determined by HPLC analysis, after isolation and acid hydrolysis of 
DNA, as previously described [11]. 
2.3. DNA extraction and restriction endonuclease treatment 
Genomic DNA, extracted from the various samples using a stand- 
ard procedure [12], was treated separately with the following restric- 
tion endonucleases: (i) EcoRI, which has no recognition site internal 
to the amplified fragment; (ii) HpaII, which has three recognition sites 
internal to the amplified fragment and is methylation sensitive (i.e. it 
does not cut if the CCGG recognition sequence is methylated at any 
C); (iii) AvaI, which has two recognition sites internal to the amplified 
product and is methylation insensitive. In each case, 1.5 lag of ge- 
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nomic DNA were digested overnight, at 37°C, with 3 units of enzyme, 
and then with a further 3 units for an additional 6 h, in a final volume 
of 40 [al, with the buffer provided by the manufacturer. 
2.4. HpalI/PCR assay 
For amplification of the human thymidine kinase gene (GenBank, 
accession umbers M 15205, M 15206) [13], the following primers were 
used: forward primer HSTKP3, 5'-GCGGGACCAGGGGCTTACT- 
GC-3', which is complementary to exon 1 (nt 451-471); reverse 
primer HSTKM1, 5'-GGACACAGGCTATCACCACGACC-3' 
which is complementary to intron 1 (nt 624~646). This couple of 
primers was expected to produce, from uncut DNA, an amplified 
fragment of 196 bp. About 20 pmol of each primer were included 
in the reaction mixture. PCR was performed on 50 ng of DNA, in 
a final volume of 50 [al containing 10 mM Tris-HC1, pH 9.0, 50 mM 
KC1, 1.5 mM MgC12, 0.1% Triton X-100, 0.01% (w/v) gelatin, 200 [aM 
dNTPs with 1 unit of SuperTaq (HT Biotechnology LTD, UK). After 
an initial denaturation for 3 min at 94°C, a scalar number, from 20 to 
35, of cycles (1 rain at 94°C, 1 min at 58°C, 1.5 min at 72°C) and a 
final extension of 5 min at 72°C were performed in a Perkin Elmer 480 
Thermal Cycler. By this HpaIIIPCR assay [14,15] an amplified prod- 
uct could be obtained only if the DNA fragment o be amplified by 
the specific couple of primers, failed to be cut by a restriction endo- 
nuclease. The analysis of the amplified products obtained from the 
HpaII-treated samples allows the determination of the methylation 
status of three CCGG sites in exon l of TK gene. The EcoRI-treated 
samples were used as positive controls and the AvaI-treated samples 
as negative ones. 
2.5. Gel eleetrophoresis and analysis' of PCR products 
The PCR products were evaluated by electrophoresis, in 1.5% agar- 
ose gel, of 15 ~tl of the PCR reaction. Each gel was scanned by a CCD 
camera nd acquired on a Bio Image (Millipore, USA) computerized 
densitometer. Fragment size and relative abundance (expressed as 
optical density) were calculated by the system. The amplified products 
were recovered from the gel using Amicon filters (Micropure 
0.22+Microcon 50) and the specificity of the fragments was assessed 
by restriction analysis. The intensity of amplified products obtained 
after HpaII treatment of the samples was normalized to the intensity 
of amplified products obtained after EcoRI treatment, both measured 
densitometrically and expressed as optical density units. 
3. Results and discussion 
Human lymphoblastoid CEM cells and the AZT-resistant 
MT500 variant cell line were exposed for 48 h to increasing 
concentrat ions of AZT, ranging from 5 ~tM to 1 mM for the 
parental drug-sensitive and from 5 to 150 ~tM for the resistant 
Table 1 
Effect of AZT treatment on DNA methylation of CEM and MT500 
cells 
AZT ([aM) % methylcytosine 
CEM MT500 
0 3.32 _+ 0.08 3.29 + 0.10 
5 3.30+0.10 3.28_+0.15 
(99.4%) (100.0%) 
75 3.38 _+0.12 3.91 +0.1 
(101.8°/,,) (118.8%) 
150 3.40_+0.25 3.21 _+0.12 
(102.4%) (0.98%) 
300 3.38 _+0.15 N.D. 
(101.8%) 
600 3.16 _+ 0.09 N.D. 
(95.2%) 
1000 3.42 _+ 0.34 N.D. 
(1o3.oo/,0 
Data are expressed as the mean of percentages of methylcytosine over 
total cytosine from three independent experiments+ S.D. In paren- 
theses are reported the percentages with respect o untreated cells. 
N.D., not determined. 
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Fig. I. AZT effect on the growth of CEM (A) and MT500 (B) cells 
exposed to different AZT concentrations for the indicated times. 
Cell viability was determined by MTT assay. Percentages are re- 
ferred to the growth of cells incubated in the absence of AZT. 
White bars: 150 gM AZT, grey bars: 600 [aM AZT, black bars: 
1000 [aM AZT. 
variant. The incubation was performed in the presence of 
[3H]uridine in order to measure the percentage of 5-methylcy- 
tosine. There was little or no difference, between CEM cells 
and MT500 resistant cell variant, in total DNA methylation in 
either the presence or absence of AZT  (Table 1). Under  these 
conditions, cell viability of CEM sensitive cells was reduced 
(after 48 h) to approx. 50%, and to even lower values, after 72 
h at the highest drug concentrat ion (Fig. 1). 
We have also assessed the effect, in CEM cells, of some 
compounds known to induce, in other cell lines [16], different 
levels of DNA hypermethylation. As reported in Table 2 only 
cisplatinum caused, after 48 h, a 143% increase in methyla- 
tion, while none of the other drugs significantly affected 5- 
methylcytosine l vels. 
Considering that HPLC analysis of total DNA methylat ion 
levels could be not sensitive nough to detect small variations 
in the methylation status of specific sites, but that even minor 
alterations might be highly effective in modulat ing the expres- 
sion of genes to which these sites are associated, we have used 
the HpaI I /PCR assay in order to analyze the methylat ion 
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Fig. 2. HpaII/PCR assay performed on the three CCGG sites of exon l of human TK gene. (A) Amplified products from EcoRI-treated DNAs 
(lanes 1 5) or from HpaII-treated DNAs (lanes (~10), extracted from CEM cells not treated (lanes 1,6) or treated with 150 laM (lanes 2,7), 300 
laM (lanes 3,8) and 600 I.tM (lanes 4,9) AZT. In lanes 5 and 10 the results relative to MT500 cell line variant exposed to 2 mM AZT are 
shown. (B) Semiquantitative output obtained by normalization of the optical density (O.D.) of signals relative to HpaII-treated samples with 
that of signals relative to EeoRI-treated samples. (The value relative to the MT500 cell line variant was set to 100%.) 
status o f  three specific CCGG sites in exon 1 o f  TK  gene. Fig. 
2A shows the amplif ied products  obta ined after HpaII treat- 
ment  o f  DNA extracted f rom untreated (lane 6) and AZT-  
treated (lanes 7 9) CEM cells. The amplif ied product  obta ined 
Table 2 
Effect of various compounds on DNA methylation of CEM cells 
Compound Duration of treatment (h) % methylcytosine 
None 24 3.24 
48 3.27 
l mM 5-fluorouracil 24 3.17 
48 3.30 
100 ~tM cisplatinum 24 3.09 
48 4.43 
1 mM 1-[3-D-arabinofuranosylcytosine 24 3.93 
48 3.12 
100 I.tM 2',3'-dideoxyinosine 24 3.04 
48 3.18 
Data are expressed as in Table 1. 
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from HpaII-treated DNA extracted from MT500 cells exposed 
to 2 mM AZT for 48 h is shown in lane 10. Lanes 1 5 show 
the amplified products obtained from DNA treated with 
EcoRI, which has no recognition site internal to the sequence 
to be amplified, and is therefore used as a positive internal 
control of the amplification. It can be noted that the EcoRI- 
treated samples produced similar quantities of amplified prod- 
ucts, whereas, among the HpaII-treated samples, the intensity 
of the amplified product was lowest in the control CEM sam- 
ple, highest in the MT500 resistant cell line variant and of 
intermediate l vel in the AZT-treated CEM samples. The lin- 
earity range of the assay was assessed performing amplifica- 
tions with a scalar number of cycles (from 20 to 35), and we 
verified that, within the linearity range, the amount of ampli- 
fied products was proportional to the amount of initial DNA 
target in the EcoRI-treated samples. In the HpaII-treated 
samples, the level of amplified products was proportional to 
the initial amount of uncut target, i.e. to the initial amount of 
methylated sequences (data not shown). It can be concluded 
that methylation is highest in the resistant MT500 and lowest 
in the sensitive CEM parental line. AZT-treated CEM cells 
showed intermediate levels of methylation. No amplified 
products were present in AvaI-treated samples (data not 
shown). A semiquantitative output can be obtained by refer- 
ring the optical density of the amplified products relative to 
the HpaII-treated samples to that of the corresponding 
EcoRI-treated samples (Fig. 2B). 
MT500, an AZT-resistant cell line obtained in our labora- 
tory and able to grow in the presence of 2 mM AZT, has been 
found to have an approx. 20-fold reduction in TK activity 
[10]. A similar defect in TK  activity has been suggested to 
occur, in other cell lines [5,9], as a consequence of AZT-in- 
duced genome-wide DNA hypermethylation. Drug-induced 
DNA hypermethylation has indeed been observed as part of 
the response of various cell lines to the cytotoxic effect of 
several antitumor agents [16]. However, with these com- 
pounds and with AZT, the global hypermethylation effect 
was found only under conditions of marked inhibition of 
DNA synthesis and 90 100% cell death, determined by con- 
centrations of drugs unsuitable for clinical practice. The con- 
ditions and the cell lines we used for AZT treatment, showed 
instead, even in the parental CEM cells, no severe immediate 
loss of cell viability, although the changes occurring within the 
first 48 h of culture will, later on, result in the block of rep- 
lication and finally in cell death. No genome-wide DNA hy- 
permethylation was found to take place during this time inter- 
val. A highly significant alteration in the methylation pattern 
of exon 1 of the TK gene could instead be detected in CEM 
cells treated with AZT and even more, always in the absence 
of a more generalized hypermethylation, i  the resistant clone 
MT500. These results support the hypothesis that a fairly 
specific hypermethylation of the TK gene is associated with 
both short-term cell survival in the presence of AZT and with 
selection of a stable AZT resistance. 
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